title: Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients.
abstract: OBJECTIVE
  Earlier studies have demonstrated that the uterine papillary serous carcinoma (UPSC) variant of endometrial carcinoma has a high recurrence rate, even when disease is apparently confined to the uterus. The current study evaluated survival in patients with surgically staged UPSC.
  
  
  METHODS
  Patients with UPSC were identified from surgical pathology files and charts were retrospectively reviewed. Only patients who had undergone a TAH-BSO, lymph node dissection, and peritoneal cytology were included.
  
  
  RESULTS
  The FIGO stages of the 36 patients were 12 Stage I (4 IA, 4 IB, 4 IC), 2 Stage IIB, 13 Stage III (5 IIIA, 8 IIIC), and 9 Stage IV. Of the 14 Stage I/II patients, 6 did not receive adjuvant therapy, 5 received whole pelvic radiation (WPXRT), and 3 received whole abdominal radiation therapy (WART); after a median follow-up interval of 50 months only 2 (14%) of these Stage I/II patients have developed a recurrence. Both of the recurrences were in Stage IC patients who received radiation; 1 recurred in the radiation field. Of the 5 Stage IIIA patients, 3 patients declined therapy and 2 were treated with WART; 3 patients, including the 2 who received radiation therapy, are alive without disease. Of the 8 Stage IIIC patients, 2 declined postoperative therapy, 2 received WART, and 4 received WPXRT with an extended field to include paraaortic nodes. Four of the 6 Stage IIIC patients treated with curative intent are without evidence of disease and 1 died of unrelated causes after a median follow-up interval of 48 months. Both of the Stage IIIC patients who declined treatment recurred. Of the 9 patients with Stage IV disease, 8 have died of disease.
  
  
  CONCLUSIONS
  Women with UPSC have a good prognosis when surgical staging confirms that disease is confined to the uterus (Stage I/II). Surgical findings can also be used to tailor adjuvant radiation treatments. Further study is required to define the optimal treatment for women with metastatic UPSC.
authors.affiliation: Department of Obstetrics and Gynecology, Seattle, Washington 98195, USA.
authors.forename: J
authors.initials: J
authors.lastname: Grice
authors.forename: M
authors.initials: M
authors.lastname: Ek
authors.forename: B
authors.initials: B
authors.lastname: Greer
authors.forename: W J
authors.initials: WJ
authors.lastname: Koh
authors.forename: H G
authors.initials: HG
authors.lastname: Muntz
authors.forename: J
authors.initials: J
authors.lastname: Cain
authors.forename: H
authors.initials: H
authors.lastname: Tamimi
authors.forename: K
authors.initials: K
authors.lastname: Stelzer
authors.forename: D
authors.initials: D
authors.lastname: Figge
authors.forename: B A
authors.initials: BA
authors.lastname: Goff
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018283:Cystadenocarcinoma, Papillary / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000379:methods; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery